TNF inhibitor

Article

Troubles with ‘Gut Feelings’ (10.16.2026)

Jack Cush, MD Oct 16, 2026

Dr. Jack Cush reviews this week's news from RheumNow.com, including: placebo trumps controversial therapies, the dynamics of disease activity, fuse the big toe, and patients don’t appreciate being told “its all in your head”!

French National Health System study of 214,892 #RA pts (~40K on TNFi) found 562 demyelinating events (2008-2023) w/ cumulative 10 yr incidence of 0.32% w/ csDMARDs & 0.50% w/ TNFi (HR 1.47;1.11-1.95). Demyelinating events are rare in RA, but signif higher w/ TNFi https://t.co/6vUy5nsQ27

Funny! Dr. Glaucomflecken explains the REPLENISH trial -secukinumab for the treatment of polymyalgia rheumatica https://t.co/7JDoMDJzeD https://t.co/ZBMcheSeCv

Dr. Glaucomflecken Explains: Secukinumab in Polymyalgia Rheumatica | NEJM

Observational study of 228 #PsA pts Rx biologics, either early (<2yrs; mean 6 mos) vs later (mean 3.6 yrs). Groups were balanced in all parameters; after 6 mos no diff in DAPSA50 or PASI75 response. Biologics work regardless of when started. https://t.co/ZCDR8l2CsI https://t.co/PHgtgZu12G

Short‐Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influence…

Article

Remission – Believe it or Not (10.2.2026)

Jack Cush, MD Oct 02, 2026

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Do biologic Rx lower risk of PsA? Metanalysis (15 studies, 124,138 psoriasis pts, 778K PYrs F/U), showed Biologic use assoc w/ lower risk of PsA (HR 0.54); best for IL-17i (0.65) & IL-12/23 or IL-23i (0.46) vs TNFi. IL-23i superior to IL-17i (HR 0.67) https://t.co/pjZZJ8yq9A https://t.co/yIwQs2FwLW

Impact of Biologic Therapies on the Risk of Progression from Psoriasis to Psori…

It’s almost time. 🔥 Registration for RheumNow Live 2027 opens OCTOBER 1. Two days of practical, engaging rheumatology education designed to challenge how you think and influence how you practice. 📅 Jan 30–31, 2027 📍 Dallas + Online https://t.co/Ju0zzYX8Tl

True or False: The TriNetX retrospective study found that JAK inhibitors significantly increased VTE risk in rheumatoid arthritis patients undergoing hip or knee replacement compared to TNF inhibitors. Check your knowledge in the latest RheumIQ quiz at https://t.co/LHFv1P6XZe.

RheumIQ Weekly Quiz | RheumNow

TriNetX retrospective EHR study showed VTE in #RA not incr by taking JAKi. Pts undergoing THA/TKA Rx w/ JAKi (n 284) vs TNFi (n 288). VTE- 17 JAKi (6%) vs 11 TNFi (3.8%)- nonsignif incr (RR 1.57) https://t.co/OM5ipieQtr https://t.co/ng8b9EkWmT

Venous Thromboembolism Risk Following Total Joint Arthroplasty in Rheumatoid Ar…

RheumIQ: In axial spondyloarthritis, obesity reduces TNF inhibitor responses by how much? Test your knowledge at https://t.co/UaXqHKWizt.

RheumIQ Weekly Quiz | RheumNow

Article

JAMA: Review of Adult Rheumatoid Arthritis

Jack Cush, MD Sep 10, 2026

Smolen, Kerschbaumer, Aletaha, and Robinson have published a comprehensive review article of rheumatoid arthritis (RA) in JAMA, noting significant changes to our understanding and treatment guidelines.

Article

Obesity in Axial Spondyloarthritis: what are we missing beyond the scale?

Antoni Chan, MD, PhD Sep 10, 2026

Obesity in axial spondyloarthritis (axSpA) is not a minor comorbidity. Beyond the scale, there are several factors that need to be considered with obesity in axSpA.

High BMI decreases the odds for MDA in PsA, esp w/ TNFi Rx (but not Inflx, IL-17i, IL-12/23i, IL-23i, JAKi). Longitudinal PsA cohort 1291 pts (mean BMI 29); Higher BMI independently assoc w/ signif. lower odds for MDA (OR 0.97), also female, age, smoking, FM & Xray damage. https://t.co/zAJ8Pmk1HY

Article

“ABCDE” Approach to Difficult-to-Treat Rheumatoid Arthritis

Jack Cush, MD Sep 02, 2026

The proposed approach to difficult-to-treat rheumatoid arthritis is based on the EULAR definition (having failed 2 or more b/tsDMARDs). The authors provide guidance in the form of an easy acronym, A B C D E, which covers both diagnostic and therapeutic considerations.

Rheums! Do you have a Rheumatology question or case for Dr. Cush? Record it here, and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/LZ59KW8HdA https://t.co/DwHdvpTYax

Submit Podcast Question or Comment | RheumNow

SELECT-PsA 2 subanalysis of 195 active PsA not responding to TNFi shows switching to upadacitinib 15 (vs PB) was superior @wk 24 - ACR20 (58% vs 22%), ACR50 (38% vs 9.5%), ACR70 (22% vs 0%), MDA (24% vs 3%) & maintained thru wk 152. Switching MOAs makes sense! https://t.co/YEkZuQ95Mu

Resolved HBV infx (HBsAg-neg/anti-HBc+) retrospective study of HBc seroclearance in 230 pts Rx w/ anti-CD20 mAb. anti-HBc seroclearance seen in 16.5% (assoc w/ Younger age, less CD20 Rx, MMF Rx). HBV reactivation seen 5/230 (2.2%), including two w/ HBc seroclearance. HBc https://t.co/T0gfxftOgu

True or False: A meta-analysis of 61 studies found that exercise showed anti-inflammatory trends, including reductions in CRP, IL-6, and TNF-α, in most chronic diseases. Test your knowledge in this week's RheumIQ at https://t.co/TBlB4pmnKa. https://t.co/7MxkveOuZE

RheumIQ Weekly Quiz | RheumNow

Article

NME: New Molecular Entities (8.28.2026)

Jack Cush, MD Aug 28, 2026

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. Take this week's RheumIQ and test your knowledge!

Does exercise affect inflammatory biomarkers? Metanalysis of 61 studies shows mostly low certainty evidence of inflammation-modulating effects of exercise. In most chronic diseases, exercise showed anti-inflammatory trends w/ reductions in CRP, IL-6, TNF-α https://t.co/EP74b3mVAT https://t.co/WBTHjsCzKL

Frontiers | The impact of exercise on inflammatory biomarkers: an umbrella revi…

VA study of 4108 RA-ILD (2006-21). PRED use was 65-77%, A& 1st line Rx (MMF, AZA, RTX, CTX) incr after ILD, use was low (1.2-12%). MTX decr (47 to 30%), but LEF, TNFi, ABA incr. Predictors of ILD Rx: FVC, CCP+, ILD Dx after 2012. https://t.co/GT3Vwo11w1 https://t.co/KFDKsjkN0k

Real‐World Treatment Patterns in Rheumatoid Arthritis–Associated Interstitial L…

Prolonged exposure to targeted Rx in #SpA not assoc w/ increased cancer risk. French claims study 56,591 SpA pts- 1,224 CA (1,029 solid, 116 Heme). TNFi, IL17i, IL12/23i, IL23i, JAKi Exposure >6 vs ≤6 mos assoc w/ lower CA (HR 0.86; 0.75-0.99); signif for Heme (HR 0.65), not https://t.co/rHAa0CkAjT

French study of 90 RA F pts w/ 100 pregnancies (steroids 46% & biologics 39% were used). Vs 359 controls, RA had signif. more preterm birth (PTB;OR 2.08) & small for gestational age. SGA assoc w/ nulliparity (adj OR 4.38), PTB assoc w/ maternal age (aOR 1.14) & GC ≥10 mg/d (aOR https://t.co/StCJW2rsZI

ZEUS Trial: IL-6 Inhibition Fails to Cut Cardiovascular Events The phase 3 ZEUS trial tested the IL-6 ligand inhibitor ZVK in over 6,000 patients with ASCVD, CKD, and elevated hsCRP. Although ZVK significantly lowered IL-6 and CRP levels, it did not improved outcomes (HR 0.99 https://t.co/jf2gAtvmpZ

FDA & Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab biosimilar) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles. Applies to NDC Number 65219-594-20, Lot Number 16UI07 , Expiration date: 08/2028 . FDA warns possible ISR or VTE. https://t.co/YMRC9FO7Mu

Therapeutic Updates

A JAKi After TNFi Failure in RA: SELECT-SWITCH at Week 12

Sponsored by AbbVie Medical Affairs + Health Impact

Aug 01, 2026

Dr. Christina Charles-Schoeman and Dr. Manish Jain are back to discuss treatment considerations after TNFi failure in RA. Join them as they review the latest data from SELECT-SWITCH, including post hoc results in primary and secondary nonresponders presented at EULAR 2026.

Read Post